The prognostic significance of multiple pelvic node metastases in cervical cancer patients treated with radical hysterectomy plus adjuvant chemoradiotherapy

International Journal of Gynecological Cancer

Volumn 22, Issue 3, 2012, Pages 490-497

  Okazawa, Mika ^a   Mabuchi, Seiji ^a   Isohashi, Fumiaki ^a   Suzuki, Osamu ^b   Ohta, Yukinobu ^a   Fujita, Masami ^a   Yoshino, Kiyoshi ^a   Enomoto, Takayuki ^a   Kamiura, Shoji ^a   Kimura, Tadashi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Adjuvant radiotherapy; Cervical cancer; Chemoradiotherapy; Pelvic node metastasis; Radical hysterectomy; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHILD; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MEDICAL RECORD; PELVIS LYMPH NODE; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADICAL HYSTERECTOMY; SCHOOL CHILD; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CHEMORADIOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYSTERECTOMY; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; PELVIS; PROGNOSIS; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84858185909     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31823c369b     Document Type: Article

References (31)

1. Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage IB-IIA cervical cancer. Lancet. 1997;350:535-540. (Pubitemid 27348428)
2. Morley GW, Seski JC. Radical pelvic surgery versus radiation therapy for stage I carcinoma of the cervix (exclusive of microinvasion). Am J Obstet Gynecol. 1976;126:785-798. (Pubitemid 8001360)
3. Perez CA, Camel HM, Kao MS, et al. Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage IB and IIA carcinoma of the uterine cervix: final report. Gynecol Oncol. 1987;27:129-140. (Pubitemid 17065822)
4. Kasamatsu T, Onda T, Sawada M, et al. Radical hysterectomy for FIGO stage I-IIB adenocarcinoma of the uterine cervix. Br J Cancer. 2009;100:1400-1405.
5. Benedet JL, Odicino F, Maisonneuve P, et al. Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2003;83:41-78. (Pubitemid 39658495)
6. Delgado G, Bundy B, Zaino R, et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1990;38:352-357. (Pubitemid 20362555)
7. Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group study. Gynecol Oncol. 1999;73:177-183. (Pubitemid 29215728)
8. Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006;65:169-176.
9. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606-1613. (Pubitemid 30220538)
10. Monk BJ, Cha DS, Walker JL, et al. Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma. Gynecol Oncol. 1994;54:4-9. (Pubitemid 24239400)
11. Sakuragi N, Satoh C, Takeda N, et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy. Cancer. 1999; 85:1547-1554. (Pubitemid 29152827)
12. Inoue T, Morita K. The prognostic significance of number of positive nodes in cervical carcinoma stages IB, IIA, and IIB. Cancer. 1990;65:1923-1927. (Pubitemid 20147629)
13. Kamura T, Tsukamoto N, Tsuruchi N, et al. Multivariate analysis of the histopathologic prognostic factors of cervical cancer in patients undergoing radical hysterectomy. Cancer. 1992;69:181-186.
14. Lai CH, Chang HC, Chang TC, et al. Prognostic factors and impacts of adjuvant therapy in early-stage cervical carcinoma with pelvic node metastases. Gynecol Oncol. 1993;51:390-396. (Pubitemid 24058617)
15. Stock RG, Chen AS, Flickinger JC, et al. Node-positive cervical cancer: impact of pelvic irradiation and patterns of failure. Int J Radiat Oncol Biol Phys. 1995;31:31-36.
16. Tsai CS, Lai CH, Wang CC, et al. The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy. Gynecol Oncol. 1999;75:328-333.
17. Aoki Y, Sasaki M, Watanabe M, et al. High-risk group in node-positive patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation. Gynecol Oncol. 2000; 77:305-309. (Pubitemid 30317154)
18. Kim JH, Kim HJ, Hong S, et al. Post-hysterectomy radiotherapy in FIGO stage IB-IIB uterine cervical carcinoma. Gynecol Oncol. 2005;96:407-414. (Pubitemid 40127142)
19. Park JY, Kim DY, Kim JH, et al. Further stratification of risk groups in patients with lymph node metastasis after radical hysterectomy for early-stage cervical cancer. Gynecol Oncol. 2010;117:53-58.
20. Hosaka M, Watari H, Mitamura T, et al. Survival and prognosticators of node-positive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy. Int J Clin Oncol. 2011;16:33-38.
21. Mabuchi S, Morishige K, Isohashi F, et al. Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors. Gynecol Oncol. 2009;115:482-487.
22. Mabuchi S, Okazawa M, Isohashi F, et al. Postoperative whole pelvic radiotherapy plus concurrent chemotherapy versus extended-field irradiation for early-stage cervical cancer patients with multiple pelvic lymph node metastases. Gynecol Oncol. 2011;120:94-100.
23. Mabuchi S, Isohashi F, Yoshioka Y, et al. Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy. Int J Gynecol Cancer. 2010; 20:834-840.
24. Monk BJ, Wang J, Im S, et al. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol. 2005;96:721-728. (Pubitemid 40255492)
25. Duenas-Gonzalez A, Zarba JJ, Patel F, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011;29:1678-1685.
26. Kitchener HC, Hoskins W, Small W Jr, et al. The development of priority cervical cancer trials: a Gynecologic Cancer InterGroup report. Int J Gynecol Cancer. 2010;20: 1092-1100.
27. Varia MA, Bundy BN, Deppe G, et al. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 1998;42:1015-1023. (Pubitemid 29004143)
28. Grigsby PW, Perez CA, Chao KS, et al. Radiation therapy for carcinoma of the cervix with biopsy-proven positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys. 2001;49:733-738. (Pubitemid 32112198)
29. Podczaski E, Stryker JA, Kaminski P, et al. Extended-field radiation therapy for carcinoma of the cervix. Cancer. 1990;66:251-258. (Pubitemid 20205904)
30. Kodaira T, Fuwa N, Nakanishi T, et al. Prospective study of alternating chemoradiotherapy consisting of extended-field dynamic conformational radiotherapy and systemic chemotherapy using 5-FU and nedaplatin for patients in high-risk group with cervical carcinoma. Int J Radiat Oncol Biol Phys. 2009;73:251-258.
31. Beriwal S, Gan GN, Heron DE, et al. Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2007;68:166-171. (Pubitemid 46589834)